Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?
- 30 June 2004
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 5 (6) , 525-531
- https://doi.org/10.1016/j.ccr.2004.05.028
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast CancerBreast Cancer Research and Treatment, 2003
- Mutational Analysis of the Tyrosine Kinome in Colorectal CancersScience, 2003
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor TypesJournal of Clinical Oncology, 2002
- Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor BetaNew England Journal of Medicine, 2002
- Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthCancer Cell, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2Oncogene, 2002
- Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor InhibitionJournal of Clinical Oncology, 2002
- Oncogenic kinase signallingNature, 2001
- Constitutive Activation of c-Jun N-terminal Kinase by a Mutant Epidermal Growth Factor ReceptorJournal of Biological Chemistry, 1998